Sanofi (SNY)

NasdaqGS - NasdaqGS Real-time price. Currency in USD

Add to watchlist

56.25

-1.06

(-1.85%)

At close: 04:00PM EDT

56.02

-0.23

(-0.41%)

Pre-market:

06:36AM EDT

Loading interactive chart…

Bloomberg
Sanofi Is Said to Ask Bidders to Revise Consumer Health Offers
(Bloomberg) -- Sanofi has asked bidders to revise their proposals for its consumer health unit, people with knowledge of the matter said, as it considers whether to seek a sale or listing of the business. Most Read from BloombergA 7,000-Year-Old City Emerges as a Haven from Dubai’s Sky-High RentsGang Violence Is Moving to the Amazon’s Fast-Growing CitiesA Housing Crisis Brews in Rwanda’s Capital CityNew Rowhouses in London That Offer a Bridge to the 19th CenturyClimate Migrants Stand to Overwhel
Zacks
Sanofi, Regeneron's Dupixent Gets FDA Approval for COPD
Sanofi and Regeneron's Dupixent becomes the first biologic treatment approved for COPD in the United States.
Investor's Business Daily
Regeneron And Sanofi Snag Their $6 Billion-Potential COPD Approval For Dupixent
Regeneron stock rose Friday after the company won FDA approval for Dupixent in chronic obstructive pulmonary disease, or COPD.